The content on this site is intended for healthcare professionals only
The use of maintenance treatments in myeloma patients
Key advances in the treatment of lymphoma from ASH 2010
Optimal treatment of multiple myeloma
The history of bendamustine
The role of bendamustine in the treatment of mantle cell lymphomas
First-line Indolent Trial (FIT) study
Changing the paradigm in frontline CML therapy
Burkitt’s lymphoma in the elderly
The role of comorbidity indices in the prognosis of elderly MDS patients
Key research presented at ASH 2010
DASISION study on cardiovascular safety in patients with CML-CP
The role of epigenetics in cancer treatment
Progress in the treatment of CML
Blood cancers in the elderly
Key CML research from ASH 2010
Advances in the treatment of CLL
The role of plasma cell biology in multiple myeloma
Key multiple myeloma research from ASH 2010
CLL related research from ASH 2010
The DASISION chronic myeloid leukaemia trial
Key lymphoma research from ASH 2010
The importance of myelodysplastic syndrome diagnosis
Haematological cancers in the elderly
ENESTnd trial comparing nilotinib and imatinib as first line CML therapy
Administration of bortezomib in multiple myeloma patients
Bosutinib as a treatment for newly diagnosed chronic myeloid leukaemia
Inotuzumab ozogamicin therapy for indolent B-cell non-Hodgkin's lymphoma
Temsirolimus and clofarabine for the treatment of elderly AML patients
The treatment of haematological cancer in older patients
ecancer symposium on the treatment of elderly patients with haematological cancer
Senior Adult Oncology Program at Moffitt Cancer Center
Factors influencing treatment of elderly cancer patients
Ofatumumab treatment for chronic lymphocytic leukaemia
Role of bortezomib in the treatment of follicular lymphoma
Haematological cancers in the elderly
The role of the European Hematology Association
Haematological cancer in the elderly
